Yourgene Health Share Discussion Threads

[toyin] 16/1/2019 11:01

twix386. I don't think he ever said 30p. I remember 25p before placing because of dilution he dropped to 21p.

[timojelly] 16/1/2019 10:26

I think we are moving rapidly back to 15p.

[christopher logsdon] 16/1/2019 07:11

I agree with your sentiment he says massive upside I don't think 21p is massive

[christopher logsdon] 16/1/2019 07:10

Very good question send him an email

[twix386] 15/1/2019 23:59

So why does TW have a target to sell of 21p and yet a 6 month bearcast expectation of 30p!

[hjb1] 15/1/2019 20:36

he might just be right this time for once?

[the monkster] 15/1/2019 19:57

6 month target 30p. Again

[hjb1] 15/1/2019 19:10

anyone hear what TW had to say in his bearcast today?

[mhw28865] 15/1/2019 11:40

Looking good hope your right Tim!

[timojelly] 15/1/2019 11:37

Next stop 20p

[christopher logsdon] 15/1/2019 10:22

Copyright !

[timojelly] 11/1/2019 13:25

Looks like we are heading back above 10p at least.

[bioking] 08/1/2019 13:02

OT) Please look at Futura Medical (FUM) has a dirt low market cap of 19 Million and has 3 Drugs including a potential MEGA Blockbuster in Phase 3 for the treatment of erectile dysfunction which works way faster than market leaders like Viarga and Cialis . If you look for a potential 10+ Bagger then load up FUM stock alreay jumping higher check it out guys


Research Confirms MED2002's US$1 Billion Potential
hxxps://futuramedical.com/content/news/archive17/060317b.asp

The latest market research further endorses Futura's strategy of developing MED2002 as a prescription product in standard and increased strength dose forms, with the objective of switching the standard dose form to an OTC product at an appropriate time.

Ipsos's validated healthcare forecasting model was used to predict peak OTC annual sales for MED2002 in key countries worldwide in excess of US$650 million. This forecast follows earlier market research commissioned into the potential of MED2002 as a prescription product, which indicated a prescription market size of up to US$600 million in key countries worldwide.

Ipsos forecasts that 70% of OTC product sales will be incremental to the prescription ED category. As a result, the estimated peak annual sales of MED2002 in prescription and OTC versions is predicted to be more than US$1 billion prior to the expiry of the product's expected patent life.

The Ipsos valuation was based on the outcomes from primary market research carried out amongst 400 men with ED or suspected ED in the USA. The respondents were in four groups: satisfied users of PDE5 inhibitors (the class of drugs such as Viagra and Cialis); dissatisfied users of PDE5 inhibitors; diagnosed but untreated ED sufferers; and suspected though undiagnosed ED sufferers. The respondents were shown a concept about MED2002 as part of the market research though they did not use the product as it is currently in clinical development.

The key findings of the market research showed that the respondents believed that the product, once approved, is highly differentiated from existing products and that its claims would meet their needs. MED2002's rapid onset of action, an average of less than five minutes, was the key feature that attracted respondents to the product and could command a price premium compared with existing ED treatments, which have a substantially slower onset of action.

The Ipsos healthcare forecasting model has been demonstrated by Ipsos to be within 20% of actual sales volumes in 9 out of 10 of its forecasts.


Pipeline
hxxps://www.futuramedical.com/media/144144/Pipeline-2018.jpg

MED2002 (topical treatment for erectile dysfunction) hxxps://futuramedical.com/content/products/med_2002.asp

first patient dosed: in Q3/Q4 2018
Last patient dosed: by end of June 2019
Headline efficacy results: by end of December 2019

CSD500: Erectogenic condom
hxxps://futuramedical.com/content/products/csd_500.asp

Significant milestone achieved with approval of 2-year shelf life approved for CSD500, the erectogenic condom in September 2018. Development now complete. Discussions are ongoing with current and potential further distribution partners on next steps with the product in a number of markets.

Pain relief products: TPR100 (diclofenac) and TIB200 (ibuprofen) hxxps://futuramedical.com/content/products/tpr_100.asp

TPR100 commercial partner Thornton & Ross filed for UK regulatory submission in July 2018.
Out-licensing discussions for TPR100 outside of the UK are ongoing.

[small crow] 08/1/2019 12:45

I'm not proposing it - just explaining why. I'm holding fast for over 60p.

[hjb1] 08/1/2019 10:42

not much selling atm though! Still plenty of good news to come.

[small crow] 08/1/2019 10:22

Sell on news ....

[folderboy] 08/1/2019 08:34

What possible interpretation makes this bad news? Possibly less good news than those who added had expected/been told - or simply taking a profit.

Will add.

[the monkster] 08/1/2019 07:40

...and down 2 on the news no doubt!

[the monkster] 08/1/2019 07:39

Slam dunk insider trading if u ask me.

[small crow] 08/1/2019 07:30

RNS: Looks like significant technical upgrade over the competition. Higher profit margins for operators ..... more operators move to YGEN??

[timojelly] 08/1/2019 07:17

Great news. THERMO still very happy then.

[twix386] 07/1/2019 16:00

More likely Thermo debt restructuring from past expectations I'd have thought.

[jonnycj] 07/1/2019 14:35

NHS announcement related ?

[christopher logsdon] 07/1/2019 13:54

Agreed let's hope it's not just a one off fingers crossed